Risk Factors for Death from Asthma, Chronic Obstructive Pulmonary Disease, and Cardiovascular Disease After a Hospital Admission for Asthma

Overview

Journal Thorax

Date 1999 Mar 27

PMID 10092690

Citations 14

Authors

H F Guite

R Dundas

P G Burney

Affiliations

Soon will be listed here.

Abstract

Background: Patients with asthma have an increased risk of death from causes other than asthma. A study was undertaken to identify whether severity of asthma, its treatment, or associated co-morbidity were associated with increased risk of death from other causes.

Methods: Eighty five deaths from all causes occurring within three years of discharge from hospital in a cohort of 2242 subjects aged 16-64 years admitted for asthma were compared with a random sample of 61 controls aged <45 years and 61 aged >/=45 years from the same cohort.

Results: Deaths from asthma were associated with a history of clinically severe asthma (OR 6.29 (95% CI 1.84 to 21.52)), chest pain (OR 3.78 (95% CI 1.06 to 13.5)), biochemical or haematological abnormalities at admission (OR 4.12 (95% CI 1.36 to 12.49)), prescription of ipratropium bromide (OR 4.04 (95% CI 1.47 to 11.13)), and failure to prescribe inhaled steroids on discharge (OR 3.45 (95% CI 1.35 to 9.10)). Deaths from chronic obstructive pulmonary disease (COPD) were associated with lower peak expiratory flow rates (OR 2.56 (95% CI 1.52 to 4.35) for each 50 l/min change), a history of smoking (OR 5.03 (95% CI 1.17 to 21.58)), prescription of ipratropium bromide (OR 7.75 (95% CI 2.21 to 27.14)), and failure to prescribe inhaled steroids on discharge (OR 3.33 (95% CI 0.95 to 11.10)). Cardiovascular deaths were more common among those prescribed ipratropium bromide on discharge (OR 3.55 (95% CI 1.05 to 11.94)) and less likely in those admitted after an upper respiratory tract infection (OR 0.21 (95% CI 0.05 to 0.95)). Treatment with ipratropium bromide at discharge was associated with an increased risk of death from asthma even after adjusting for peak flow, COPD and cardiovascular co-morbidity, ever having smoked, and age at onset of asthma.

Conclusions: Prescription of inhaled steroids on discharge is important even for those patients with co-existent COPD and asthma. Treatment with ipratropium at discharge is associated with increased risk of death from asthma even after adjustment for a range of markers of COPD. These results need to be tested in larger studies.

Citing Articles

Clinical and Pathophysiological Tangles Between Allergy and Autoimmunity: Deconstructing an Old Dichotomic Paradigm.

Ramirez G, Cardamone C, Lettieri S, Fredi M, Mormile I Clin Rev Allergy Immunol. 2025; 68(1):13.

PMID: 39932658 PMC: 11814061. DOI: 10.1007/s12016-024-09020-3.

A Meta-Analysis on Predictors of Mortality Among Patients Hospitalized for Acute Exacerbation of Asthma.

Sado A, Afzal M, Kannekanti L, Pamreddy H, Pimentel Campillo J, Kandukuri V Cureus. 2023; 15(2):e35225.

PMID: 36968875 PMC: 10032559. DOI: 10.7759/cureus.35225.

Association Between Asthma and All-Cause Mortality and Cardiovascular Disease Morbidity and Mortality: A Meta-Analysis of Cohort Studies.

Zhang B, Li Z, An Z, Zhang L, Wang J, Hao M Front Cardiovasc Med. 2022; 9:861798.

PMID: 35369308 PMC: 8968068. DOI: 10.3389/fcvm.2022.861798.

Training needs for Ugandan primary care health workers in management of respiratory diseases: a cross sectional survey.

Nantanda R, Kayingo G, Jones R, van Gemert F, Kirenga B BMC Health Serv Res. 2020; 20(1):402.

PMID: 32393227 PMC: 7212561. DOI: 10.1186/s12913-020-05135-3.

Independent risk factors for death in patients admitted for asthma exacerbation in Taiwan.

Chang Y, Ko H, Lu M, Chou C, Su K, Hsu C NPJ Prim Care Respir Med. 2020; 30(1):7.

PMID: 32193384 PMC: 7081219. DOI: 10.1038/s41533-020-0164-4.

References

Barnes N . Inhaled steroids in COPD. Lancet. 1998; 351(9105):766-7. DOI: 10.1016/s0140-6736(98)22011-3. View

Antonelli Incalzi R, Fuso L, de Rosa M, Forastiere F, Rapiti E, Nardecchia B . Co-morbidity contributes to predict mortality of patients with chronic obstructive pulmonary disease. Eur Respir J. 1998; 10(12):2794-800. DOI: 10.1183/09031936.97.10122794. View

Bourbeau J, Rouleau M, Boucher S . Randomised controlled trial of inhaled corticosteroids in patients with chronic obstructive pulmonary disease. Thorax. 1998; 53(6):477-82. PMC: 1745246. DOI: 10.1136/thx.53.6.477. View

Bullen S . Correlation of clinical and autopsy findings in 176 cases of asthma. J Allergy. 1952; 23(3):193-203. DOI: 10.1016/0021-8707(52)90017-8. View

Paggiaro P, Dahle R, BAKRAN I, Frith L, Hollingworth K, Efthimiou J . Multicentre randomised placebo-controlled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. International COPD Study Group. Lancet. 1998; 351(9105):773-80. DOI: 10.1016/s0140-6736(97)03471-5. View

Toogood J, Baskerville J, Jennings B, Lefcoe N, JOHANSSON S . Use of spacers to facilitate inhaled corticosteroid treatment of asthma. Am Rev Respir Dis. 1984; 129(5):723-9. DOI: 10.1164/arrd.1984.129.5.723. View

Massey K, Gotz V . Ipratropium bromide. Drug Intell Clin Pharm. 1985; 19(1):5-12. DOI: 10.1177/106002808501900102. View

Persson C, Bengtsson C, Lapidus L, Rybo E, Thiringer G, Wedel H . Peak expiratory flow and risk of cardiovascular disease and death. A 12-year follow-up of participants in the population study of women in Gothenburg, Sweden. Am J Epidemiol. 1986; 124(6):942-8. DOI: 10.1093/oxfordjournals.aje.a114483. View

Charlson M, Pompei P, Ales K, MacKenzie C . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40(5):373-83. DOI: 10.1016/0021-9681(87)90171-8. View

10.

Burrows B . The natural history of asthma. J Allergy Clin Immunol. 1987; 80(3 Pt 2):373-7. DOI: 10.1016/0091-6749(87)90052-2. View

11.

Markowe H, Bulpitt C, Shipley M, Rose G, Crombie D, Fleming D . Prognosis in adult asthma: a national study. Br Med J (Clin Res Ed). 1987; 295(6604):949-52. PMC: 1248001. DOI: 10.1136/bmj.295.6604.949. View

12.

Mann K, Leon A, Tietze K . Use of ipratropium bromide in obstructive lung disease. Clin Pharm. 1988; 7(9):670-80. View

13.

Lacronique J, Renon D, Georges D, Henry-Amar M, Marsac J . High-dose beclomethasone: oral steroid-sparing effect in severe asthmatic patients. Eur Respir J. 1991; 4(7):807-12. View

14.

Sheiner L, Easterling M, Mozes B, Brown A . Laboratory data predicts survival post hospitalization. J Clin Epidemiol. 1991; 44(12):1387-403. DOI: 10.1016/0895-4356(91)90100-n. View

15.

Ryan G, Musk A, Perera D, Stock H, Knight J, Hobbs M . Risk factors for death in patients admitted to hospital with asthma: a follow-up study. Aust N Z J Med. 1991; 21(5):681-5. DOI: 10.1111/j.1445-5994.1991.tb01370.x. View

16.

Ernst P, Spitzer W, Suissa S, Cockcroft D, Habbick B, Horwitz R . Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. JAMA. 1992; 268(24):3462-4. View

17.

Mackenbach J, Kunst A, Lautenbach H, Bijlsma F, Oei Y . Competing causes of death: an analysis using multiple-cause-of-death data from The Netherlands. Am J Epidemiol. 1995; 141(5):466-75. DOI: 10.1093/oxfordjournals.aje.a117449. View

18.

Ishihara K, Hasegawa T, Okazaki M, Katakami N, Sakamoto H, Umeda B . Long-term follow-up of patients with a history of near fatal episodes; can inhaled corticosteroids reduce the risk of death from asthma?. Intern Med. 1995; 34(2):77-80. DOI: 10.2169/internalmedicine.34.77. View

19.

Weiss S, Segal M, Sparrow D, Wager C . Relation of FEV1 and peripheral blood leukocyte count to total mortality. The Normative Aging Study. Am J Epidemiol. 1995; 142(5):493-8; discussion 499-503. DOI: 10.1093/oxfordjournals.aje.a117665. View

20.

Weiner P, Weiner M, Azgad Y, Zamir D . Inhaled budesonide therapy for patients with stable COPD. Chest. 1995; 108(6):1568-71. DOI: 10.1378/chest.108.6.1568. View